Benicar, Azor, Tribenzor, Benicar HCT, And Other Blood Pressure Medicines Containing Olmesartan: Cardiovascular Mortality In Not A Side Effect Risk, Or Is It
SUMMARY: Four years ago, in June 2010, the FDA issued a Drug Safety Communication letting doctors and patients know that patients with Type 2 diabetes taking Benicar might a higher rate of death from a cardiovascular cause compared to patients taking a placebo.
In June 2014 FDA announced that the agency had completed its safety review of Benicar, finding no clear evidence of increased cardiovascular risks in diabetic patients.
So does this mean that Benicar is not associated with cardiovascular-related deaths, at all?
A well-regarded medical journalist covering cardiology news, Larry Husten, takes issue with that conclusion in his June 24, 2014 article “FDA Ends Olmesartan Safety Review, But…”.[Read this article in full at original source]
Strictly Confidential, No Obligation.